Oral Lactoferrin as a Source of Iron Supplementation in Pediatric Hemodialysis Patients
Hend Khaled Rabie Abdel Hamid;
Abstract
Summary
I
ron deficiency (ID) and iron deficiency anemia (IDA) are the most common iron disorders throughout the world. When iron requirement is higher than that absorbed, a negative iron balance occurs and iron storage decreases. Children with chronic kidney disease (CKD) may suffer from anemia due to a multi-factorial process, one of whichis disturbance in iron homeostasis. Iron homeostasis is tightly regulated through iron absorption, storage and transport.
Aim of this study is the assessment of effect of oral lactoferrin in treatment of iron deficiency anemia in children with end stage renal disease (ESRD) on hemodialysis.
In this study, 60 pediatric patients with end stage renal disease (ESRD) on regular haemodialysis in Pediatric Dialysis Unit, Children's Hospital, Ain Shams University, were trialed toevaluate the effect of oral lactoferrin on treating iron deficiency anemia instead of IV iron.
The patients were subjected to washout period of two weeks were they were not given any form of iron neither IV nor oraland this was followed by the initiation of treatment with oral lactoferrin (100 mg bovine lactoferrin) twice daily for 6 month consecutively. Clinical and laboratory evaluation were done at the start and 6 months after initiation of treatment.
In the current study on the valid cases it wasnoted that the mean change of HGB levelduring the study period had a highly significant decrease in HGB level with (p=.000) while mean iron and ferritin levels showed non significant changes with (p=.113) and (p=.194) respectively.While the TIBC level showed a highly significant decrease with (p=.003).
To conclude, oral lactoferrin could not substitute IV iron in treating iron deficiency anemia in end stage renal disease (ESRD) on dialysis.Oral lactoferrin could not even keep HGB level constant without dropping in patients with end stage renal disease (ESRD).Oral lactoferrin had some gastrointestinal effects on some patients which did not allow compliance on the medication.
Lastly according to this study, the following is recommended to be done in further studies, oral iron can be given as a treatment along with oral lactoferrin for a study to control iron deficiency anemia in end stage renal disease (ESRD).The duration of the study can be prolonged for more than six month. The dose of lactoferrin can be increased above 100mg twicedaily.
I
ron deficiency (ID) and iron deficiency anemia (IDA) are the most common iron disorders throughout the world. When iron requirement is higher than that absorbed, a negative iron balance occurs and iron storage decreases. Children with chronic kidney disease (CKD) may suffer from anemia due to a multi-factorial process, one of whichis disturbance in iron homeostasis. Iron homeostasis is tightly regulated through iron absorption, storage and transport.
Aim of this study is the assessment of effect of oral lactoferrin in treatment of iron deficiency anemia in children with end stage renal disease (ESRD) on hemodialysis.
In this study, 60 pediatric patients with end stage renal disease (ESRD) on regular haemodialysis in Pediatric Dialysis Unit, Children's Hospital, Ain Shams University, were trialed toevaluate the effect of oral lactoferrin on treating iron deficiency anemia instead of IV iron.
The patients were subjected to washout period of two weeks were they were not given any form of iron neither IV nor oraland this was followed by the initiation of treatment with oral lactoferrin (100 mg bovine lactoferrin) twice daily for 6 month consecutively. Clinical and laboratory evaluation were done at the start and 6 months after initiation of treatment.
In the current study on the valid cases it wasnoted that the mean change of HGB levelduring the study period had a highly significant decrease in HGB level with (p=.000) while mean iron and ferritin levels showed non significant changes with (p=.113) and (p=.194) respectively.While the TIBC level showed a highly significant decrease with (p=.003).
To conclude, oral lactoferrin could not substitute IV iron in treating iron deficiency anemia in end stage renal disease (ESRD) on dialysis.Oral lactoferrin could not even keep HGB level constant without dropping in patients with end stage renal disease (ESRD).Oral lactoferrin had some gastrointestinal effects on some patients which did not allow compliance on the medication.
Lastly according to this study, the following is recommended to be done in further studies, oral iron can be given as a treatment along with oral lactoferrin for a study to control iron deficiency anemia in end stage renal disease (ESRD).The duration of the study can be prolonged for more than six month. The dose of lactoferrin can be increased above 100mg twicedaily.
Other data
| Title | Oral Lactoferrin as a Source of Iron Supplementation in Pediatric Hemodialysis Patients | Other Titles | اللاكتوفيرين عن طريق الفم كمصدر لمكملات الحديد لدى مرضى الأطفال الخاضعين للغسيل الكلوى | Authors | Hend Khaled Rabie Abdel Hamid | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.